BioSpace News Archive

Protalix BioTherapeutics, Inc. today announced that it will release its financial results for the third quarter 2022 and provide a business update on Monday, November 14, 2022.

Viatris Inc. (NASDAQ: VTRS) today reported strong results for the third quarter of 2022 and reaffirmed its 2022 financial guidance.

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector device to be used in connection with its biosimilar insulin glargine and biosimilar insulin aspart development programs.

Osler Diagnostics, a medical diagnostic company aiming to transform global healthcare by providing lab-quality diagnostic testing to anyone, anywhere, at any time, announced that it has raised $85 million in a Series C financing.

Forcefield Therapeutics (“Forcefield”) Ltd, a pioneer of best-in-class therapeutics to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction, has presented positive preclinical data on three proteins identified by the FunSel platform which have potential to preserve heart function following a heart attack.

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Monday, November 14, 2022, at 8:00 a.m. EST to review business updates and its third quarter 2022 financial results.

Tango Therapeutics, Inc. today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in November.

HOOKIPA Pharma Inc. today announced it will release its third quarter 2022 financial results and Company update before the market opens on Monday, November 14, 2022.

Nabriva Therapeutics plc today announced that it will report its third quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, November 10, 2022.

Mersana Therapeutics, Inc. today provided a business update and reported financial results for the third quarter ended September 30, 2022.